{"id":"W4283020820","doi":"10.1093/noajnl/vdac085","title":"Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors","year":2022,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Cancer Institute; Cancer Research UK; Oncolytics Biotech; Mayo Clinic","keywords":"Medicine; Leukopenia; Neutropenia; Refractory (planetary science); Adverse effect; Glioma; Internal medicine; Oncolytic virus; Toxicity; Surgery; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":{"n_in":0,"stratum":"aff_core","weight":5595.2375,"opus":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"Phase I clinical trial of an oncolytic virus therapy in pediatric brain tumors."},"gpt":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"This is a phase I clinical trial of a brain-tumor therapy, not metaresearch."},"grok":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"Phase I clinical trial of oncolytic therapy in pediatric brain tumours."}},"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001108526,0.001237721,0.001346503,0.000276503,0.0003471371,0.0006202671,0.0008213416,0.0009673467,0.002328201],"category_scores_gemma":[0.0005923242,0.0003242191,0.000655196,0.0003239537,0.0006348281,0.00053191,0.0003294748,0.002657704,0.0004841561],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009566648,"about_ca_system_score_gemma":0.002105825,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008116029,"about_ca_topic_score_gemma":0.001726979,"domain_scores_codex":[0.9996984,0.0001352363,0.00001790501,0.00005049438,0.00002899601,0.00006903265],"domain_scores_gemma":[0.9994154,0.00008617593,0.00013638,0.00005023918,0.00004916932,0.0002626252],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5547322,0.09767457,0.02265941,0.001557132,0.002034793,0.001428042,0.001016598,0.006836951,0.111933,0.001195592,0.01205605,0.1868756],"study_design_scores_gemma":[0.3618935,0.6001502,0.01534852,0.00006679228,0.000406048,0.001192719,0.0001128915,0.001939765,0.01194018,0.0002862247,0.006635502,0.00002754314],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928588,0.001505025,0.0006970454,0.0004062312,0.00007727716,0.002560652,0.0007627084,0.00008549872,0.00104691],"genre_scores_gemma":[0.9844566,0.00196656,0.00353898,0.0009297284,0.0001430806,0.004784018,0.002636911,0.00003555177,0.001508669],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002328201,"threshold_uncertainty_score":0,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01852499490200818,"score_gpt":0.3361944883562387,"score_spread":0.3176694934542305,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}